About: Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment
Creator	Akahoshi, Shojiro Fuse, Yoshifumi Katae, Yuji Kawasaki, Makoto Kondo, Hideomi Ogawa, Takayuki Okazaki, Yuichi Okimoto, Nobukazu Sakai, Akinori Tsukamoto, Manabu Yamanaka, Yoshiaki Yoshioka, ·
source	Medline; PMC
abstract	INTRODUCTION: Rapid descent in bone mineral density (BMD) and ascent in bone turnover marker (BTM) occur within the short period following denosumab (Dmab) discontinuation. In addition, the incidence of vertebral fracture also rises within the short period. The purpose of this study is to investigate the effects of sequential therapy using zoledronic acid (ZOL) on any adverse events after Dmab discontinuation. MATERIALS AND METHODS: This study was a multicenter retrospective observational study, and the subjects were osteoporosis patients who visited our institutions between 2013 and 2018. We performed sequential therapy using ZOL for 30 patients who had difficulty continuing Dmab, due to physical or social reasons, and investigated the fracture incidence and BMD/BTM changes at 4 time points (at the start of Dmab, the start of ZOL, 6 months after ZOL and 12 months after ZOL). RESULTS: No new vertebral/nonvertebral fractures were observed at each time point after switching from Dmab to ZOL in any of the 30 patients. The BMD/BTM changes were evaluated in 18 of the 30 cases, since all data of lumbar/femoral neck BMDs and TRACP-5b at 4 time points was only available in 18 cases. BMDs significantly increased at each time point compared with that at the start of Dmab. Serum TRACP-5b significantly decreased at each time point compared with that at the start of Dmab. CONCLUSION: It was suggested that sequential therapy using ZOL could suppress the decrease of BMD, and increase of BTM, if the period of Dmab administration was less than 3 years. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00774-020-01126-w) contains supplementary material, which is available to authorized users.
has issue date	2020-07-12(xsd:dateTime)
bibo:doi	10.1007/s00774-020-01126-w
bibo:pmid	32656645
has license	no-cc
sha1sum (hex)	039418302972397d34d2b96597c472dcf844aa4c
schema:url	https://doi.org/10.1007/s00774-020-01126-w
resource representing a document's title	Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment
has PubMed Central identifier	PMC7354744
has PubMed identifier	32656645
schema:publication	J Bone Miner Metab
resource representing a document's body	covid:039418302972397d34d2b96597c472dcf844aa4c#body_text
is schema:about of	named entity 'fracture' named entity 'investigate' named entity 'osteoporosis' named entity 'Metabolism' named entity 'BONE MINERAL DENSITY' named entity 'MONTHS' named entity 'POINTS' named entity 'SUBJECTS' named entity 'REASONS' named entity 'This' named entity 'Dmab' named entity 'Dmab' named entity 'BMD' named entity 'BMD' named entity 'Dmab' named entity 'NSAIDs' named entity 'BMD' named entity 'Dmab' named entity 'short' named entity 'vertebral fracture' named entity 'short' named entity 'bone mineral density' named entity 'Dmab' named entity 'bone turnover' named entity 'Dmab' named entity 'Drug holiday' named entity 'BMD' named entity 'Dmab' named entity 'BMD' named entity 'DXA' named entity 'Dmab' named entity 'Dmab' named entity 'procollagen' named entity 'Dmab' named entity 'serum' named entity 'serum' named entity 'Dmab' named entity 'Dmab' named entity 'bone density' named entity 'medical records' named entity 'Dmab' named entity 'Dmab' named entity 'serum' named entity 'Quality of Life' named entity 'Dmab' named entity 'Dmab' named entity 'normal range' named entity 'Dmab' named entity 'DPX' named entity 'Dmab' named entity 'risedronate' named entity 'fragility fracture' named entity 'DXA' named entity 'osteoporotic' named entity 'Hologic' named entity 'BMD' named entity 'Dmab' named entity 'SD 11' named entity 'serum' named entity 'drug holiday' named entity 'Dmab' named entity 'serum' named entity 'serum' named entity 'therapeutic agent' named entity 'Dmab' named entity 'ECTS' named entity 'serum' named entity 'Dmab' named entity 'Dmab' named entity 'Dmab'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software